BFM
OBIO icon

Boothbay Fund Management’s Orchestra BioMed OBIO Stock Holding History

Boothbay Fund Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-298,960
Closed -$2.98M – 2497
2022
Q2 		$2.98M Buy
298,960
+93,050
+45% +$925K 0.08% 387
2022
Q1 		$2.04M Buy
205,910
+40,019
+24% +$395K 0.05% 576
2021
Q4 		$1.67M Sell
165,891
-17,115
-9% -$169K 0.04% 542
2021
Q3 		$1.81M Buy
183,006
+227
+0.1% +$2.24K 0.05% 489
2021
Q2 		$1.86M Buy
182,779
+3,200
+2% +$33.1K 0.06% 410
2021
Q1 		$2.01M Sell
179,579
-51,561
-22% -$628K 0.08% 321
2020
Q4 		$2.96M Sell
231,140
-26,113
-10% -$298K 0.11% 175
2020
Q3 		$2.83M Buy
+257,253
New +$2.89M 0.17% 141

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Boothbay Fund Management's OBIO Position: Q3 2022 in Review

Boothbay Fund Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 298,960 shares — an estimated $2.98M sold.

Boothbay Fund Management first reported a position in OBIO in Q3 2020 and held it in 8 quarters. The position peaked at $2.98M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Boothbay Fund Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 298,960 Orchestra BioMed shares in Q3 2022, an estimated $2.98M.
  • Boothbay Fund Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 8 quarters.
  • Boothbay Fund Management's Orchestra BioMed position peaked at $2.98M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.